2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 979

What Have We Learned from Trajectory Analysis of Clinical Outcomes in Osteoarthritis?

Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1029

What to Measure after Arthroplasty? Confirmation of a Core Domain Set

Health Services Research Poster II: Osteoarthritis and Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1174

Which Definition Should be Used to Determine Colchicine Resistance in Patients with Familial Mediterranean Fever?

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1412

Yra-1909 suppresses Production of Pro-Inflammatory Mediators and MMPs through Downregulating Akt, p38, JNK and NF-κb Activation in Rheumatoid Arthritis Fibroblast-like Synoviocytes

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

11:00AM-12:30PM: Abstract Number: 1788

Dose Intra-Articular Injection of Corticosteroids Increase the Risk of Knee Osteoarthritis Progression? Data from the Osteoarthritis Initiative

Plenary Session II

11:00AM-12:30PM: Abstract Number: 1787

Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Plenary Session II

11:00AM-12:30PM: Abstract Number: 1789

Improved Survival with Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System

Plenary Session II

11:00AM-12:30PM: Abstract Number: 1786

Lupus Nephritis Is Linked to Immunity to an Intestinal Commensal Lachnospiracaea Species

Plenary Session II

11:00AM-12:30PM: Abstract Number: 1785

Serious or Opportunistic Infections in Infants Born to Pregnant Women with Rheumatoid Arthritis and Treated with a Biologic Medication

Plenary Session II

11:00AM-12:30PM: Abstract Number: 1784

The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjögren’s Syndrome: A Phase IIa Double-Blind, Placebo-Controlled Randomized Trial

Plenary Session II

2:30PM-4:00PM: Abstract Number: 1803

A Cluster Analysis Approach to Patient-Physician Discordance in Rheumatoid Arthritis Activity Evaluations Optimally Differentiates and Predicts Clinical, Functional and Quality of Life Outcomes

Patient Outcomes, Preferences, and Attitudes I

2:30PM-4:00PM: Abstract Number: 1831

A Positive MRI of the Sacroiliac Joints Is Not Specific for Axial Spondyloarthritis but Frequently Occurs in Healthy Individuals

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II

2:30PM-4:00PM: Abstract Number: 1810

A Systematic Review of the Impact of Anti-Rheumatic Drugs upon Male Fertility and Paternal Exposure Peri-Conception

Reproductive Issues in Rheumatic Disorders

2:30PM-4:00PM: Abstract Number: 1817

Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry

Rheumatoid Arthritis – Clinical Aspects II: Treatment Patterns

2:30PM-4:00PM: Abstract Number: 1836

Amelioration of Neuropsychiatric Systemic Lupus Erythematosus By Fingolimod-Mediated Sphingosine-1-Phosphate Receptor Modulation

Systemic Lupus Erythematosus – Animal Models

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].